The use of neuromodulation is growing and it is an established therapy for conditions such as bladder dysfunction. It is an increasingly used therapy for the management of chronic perineal pain but little research is currently available looking at its efficacy.
INTRODUCTION
The introduction of neuromodulation has provided an additional intervention for the treatment of a variety of pelvic conditions. Its role in the management of urinary bladder dysfunction has been well documented 1 and it is now a standard treatment option.
Smaller case series have presented positive outcomes for other pelvic conditions, including sexual dysfunction, bowel dysfunction and chronic perineal pain.
Chronic pelvic pain can be complex in nature and refractory to many treatments. It can involve musculoskeletal, visceral or neurovascular mechanisms and be related to a variety of initial triggers, from pathological conditions such as endometriosis or infection, to trauma related to childbirth, assault or other injuries.
Often no triggering event or overt pathology can be identified but regardless, the pain is present and persistent. Additionally, focusing treatment to a specific trigger does not address the complexity of the mechanisms of chronic pain. T. Vancaillie et al.
Sacral neuromodulation (SNM) has been increasingly adopted for management of neuropathic pelvic pain but large scale studies on its efficacy are lacking. In addition, most of the research currently available describes lead placement through the sacral foramina (most commonly S3) with little published literature on the approach through the sacral hiatus. Other mechanisms involving the brainstem and limbic systems may also have a role. 5 Pain experienced in the perineal, anal and coccygeal regions fall into the dermatomal distribution of the L5-S5 nerve roots, thus stimulation via the sacral hiatus extending along these nerve roots is intended to disrupt the pain signals and lead to an alleviation of symptoms. While the complexity and individuality of each patient's experience of pelvic pain must be considered, those who present with a distribution of pain in these areas may be suitable for SNM. Thus, in this paper, the reference to pelvic pain should be considered as being that with a perineal focus.
Two small case series of neuromodulation via the sacral hiatus for the management of pelvic pain reported good overall efficacy. 6, 7 However, this effect did appear to wane over time.
A pilot study demonstrated positive symptom relief for pudendal neuralgia with pudendal nerve lead placement 8 and there are case reports of pain relief for the same condition using S3 and S4
foraminal lead placement. 9 In conjunction with chronic pelvic pain, many patients also suffer from sexual dysfunction. This can include dyspareunia, low desire, inability to orgasm or persistent genital arousal. Again, little evidence exists regarding the efficacy of SNM in treating these conditions. A systematic review found that improvements in sexual function after SNM were suggested but the small numbers and missing data from the included trials did not allow for conclusive interpretation of the results. 10 We present a case series of 52 patients who have been fitted with a permanent neuromodulator, the majority of who had sacral hiatal leads and the majority suffered from pelvic pain.
MATERIALS AND METHODS
Data were collected on all patients who had undergone insertion of a permanent neuromodulator device since the first implantation in the practice in 2010. At the time of initial consultation all patients were asked to sign an 'opt-out' form permitting follow-up contact. Forty-five patients consented and five forms could not be located but all patients were asked again for consent at the time of contact. One had opted out and no data were collected from that patient. As this project conforms to the standards advised by the National Health and Medical
Research Counicl for ethics quality assurance, ethics approval was not sought.
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Outcome measures
Patients were contacted either by phone or email and asked to complete a survey on their experience with the device. An initial attempt was made to contact all patients by phone. Those not contactable and those requesting to complete the survey online were emailed a copy. Multiple attempts were made to reach all patients.
The survey consisted of a series of questions regarding patients' knowledge of their device and experience with it. Those who had the device removed were asked to answer the survey reflecting upon the time during which they had the device in place.
Data were collected on case report forms and entered into the database by one of two researchers. Details on dates and placement of leads were collected from patient notes and operation reports and cross-checked with data from the manufacturer.
All patients were offered a free follow-up consultation with the operating clinician and the manufacturer's technician, regardless of whether or not they completed the survey. They were also asked if they wished to be informed about the results of the trial.
Surgical procedure
All patients surveyed in our series had undergone insertion of a permanent neuromodulator. Our current practice is to perform a trial on all patients prior to proceeding to a permanent device, the criteria for which essentially involves an improvement in symptoms and function, as judged by the patient. However, this practice has evolved over time. Initially it was the practice in some cases to proceed directly to a permanent device either in isolation or with concurrent pudendal nerve release surgery.
In total 64 patients had neuromodulation trialled or a permanent device fitted and 52 (81%) went on to insertion of a permanent device (Figure 3 ). The most commonly performed lead placement was introduction of bilateral leads through the sacral hiatus ( Fig. 1 and 2 ). Additional leads were placed in some It is routine practice for all patients to have a screening X-ray at three months to check for lead migration.
Statistical analysis
Basic summary statistics were performed using Excel. A small 
RESULTS
Between April, 2010 and May, 2016, 52 patients had implantation of a permanent neuromodulator. Patient demographics are presented in Table 1 .
The survey was completed by 43 of these patients with one survey only partially completed. Eight patients were unable to be contacted despite multiple attempts and one had died. Death was unrelated to neuromodulation.
The most common complaint prior to the procedure was pelvic pain with 40 of the surveyed patients reporting this. A review of the patient notes revealed that 44 had a diagnosis of pudendal neuralgia (this includes those who did not complete the survey).
Bladder issues, bowel issues and sexual dysfunction were the other complaints asked about and were fairly evenly reported (Table 1) .
Forty-eight patients had leads implanted via the sacral hiatus.
Of the four who did not, three had S3 leads only and one had a single hypogastric lead. The results of part two of the survey, which detailed patients' experiences, are presented in Table 2 . Overall, 35 patients reported an improvement in their quality of life, six said there was no change and two reported worsened quality of life. When asked if they would have the procedure done again, 32 said they would, four said they regretted having the procedure and six said that they did not regret it, but had found no benefit.
When asked about change in the different areas of interest, 32 patients reported that their pain was better than before implantation. Success was less marked in the other areas, with ten F I G U R E 1 Anterior-posterior view of sacral hiatal leads + S3 and S4 foraminal leads.
F I G U R E 2
Lateral view of sacral hiatal leads + S3 and S4 foraminal leads.
DISCUSSION
This study is a clinical audit of outcomes of the first 52 patients to have had placement of a permanent neuromodulator through our clinic. It is the largest published data set currently available.
Overall, 64 patients were considered appropriate for sacral neuromodulation but 12 (18.75%) did not experience a successful trial outcome and so did not go on to permanent placement. Our results suggest promise in the use of this modality as a treatment for chronic pelvic pain, with a statistically significant improvement in pain scores after implantation.
However, the interpretation is limited as the data is observational and retrospective. While the majority of our patients suffered from pelvic pain, their individual presentations and symptomatology were varied and the degree to which they suffered concurrent pelvic conditions was also varied. We attempted to review the impact of neuromodulation on sexual function but many of our patients were no longer sexually active and so the numbers were small.
Additionally, although we saw improvement in pain scores, we did not perform thorough analyses of functionality and only broadly addressed this by asking about overall quality of life. However, it is encouraging that an overwhelming majority reported an improved quality of life and overall were satisfied with their experience.
Bias is possible and this would be most marked in the pain score questions. Patients were asked to retrospectively recall their The majority of the patients in our series were female and this is reflective not only of the fact that chronic pelvic pain is more common in women but that our clinicians are practising gynaecologists. Therefore, generalisability across the genders is limited by the small male contingent and did not allow for valid comparison of outcomes between the male and female patients.
Despite these shortcomings this review certainly suggests promise in the use of sacral neuromodulation for the treatment of neuropathic pelvic pain and warrants further investigation.
Finally, other research has suggested that the efficacy of sacral neuromodulation may wane over time and so ongoing review of these patients would be of clinical value.
